Characterization of Polymyxin B-Induced Nephrotoxicity: Implications for Dosing Regimen Design

ABSTRACT The increasing prevalence of multidrug-resistant Gram-negative infections has led to renewed interest in the use of systemic polymyxin B. However, the nephrotoxic properties of polymyxin B are still poorly understood. The objective of this study was to characterize nephrotoxicity associated with polymyxin B, with an emphasis on examining the impact of dosing frequencies on the onset of nephrotoxicity. Sprague-Dawley rats were divided into two groups and administered the same total daily dose of polymyxin B subcutaneously but with different dosing frequencies (either 20 mg/kg of body weight every 24 h [q24h] or 5 mg/kg q6h). Drug concentrations in renal tissue were compared between the two groups at 24 h. Kidney tissues were harvested at 48 h and compared histologically. Serum creatinine was measured daily for up to 10 days, and nephrotoxicity was defined as a significant elevation in serum creatinine (≥2× baseline). Kaplan-Meier analysis was used to compare the onset of nephrotoxicity. Polymyxin B-induced nephrotoxicity manifested as elevation in serum creatinine and acute tubular necrosis. Extensive injury of the proximal tubules was observed. The lesions were more severe and higher drug concentrations were achieved in the kidneys of the q6h dosing group. The q24h dosing group experienced a more gradual onset of nephrotoxicity, which could be attributed to the lower kidney tissue drug concentrations (48.5 ± 17.4 μg/g versus 92.1 ± 18.1 μg/g of polymyxin B1, P = 0.04). Preferential accumulation of polymyxin B in the kidneys suggests that uptake to renal cells is a nonpassive process and q24h dosing was less nephrotoxic than q6h dosing.

[1]  K. Liewendahl,et al.  THE THERAPEUTIC SUCCESS AND NEPHROTOXICITY OF COLISTIN IN ACUTE AND CHRONIC NEPHROPATHIES WITH IMPAIRED RENAL FUNCTION. , 2009, Acta medica Scandinavica.

[2]  A Forrest,et al.  Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients , 2011, Antimicrobial Agents and Chemotherapy.

[3]  G. Drusano,et al.  Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of Nephrotoxicity , 2008, Antimicrobial Agents and Chemotherapy.

[4]  G. Drusano,et al.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  V. Tam,et al.  Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. , 2009, International journal of antimicrobial agents.

[6]  D. Landman,et al.  Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. , 2005, The Journal of antimicrobial chemotherapy.

[7]  K. Kaye,et al.  Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  G. Drusano,et al.  Back to the future: using aminoglycosides again and how to dose them optimally. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  V. Tam,et al.  Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. , 2008, The Journal of antimicrobial chemotherapy.

[10]  R. Katz RENAL AND POSSIBLY HEPATIC TOXICITY FROM COLY-MYCIN. REPORT OF A CASE. , 1963, The Medical annals of the District of Columbia.

[11]  M. Falagas,et al.  Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  V. Tam,et al.  Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms , 2008, Expert opinion on investigational drugs.

[13]  E. Federman,et al.  Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. , 1970, Annals of internal medicine.

[14]  V. Tam,et al.  Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. , 2008, Expert opinion on investigational drugs.

[15]  C. Lang,et al.  Fixatives and methods of fixation in selected tissues of the laboratory rat. , 1978, Clinical toxicology.

[16]  D. Graham,et al.  Effects of Large Doses of Colistin Sulphomethate Sodium on Renal Function , 1970, British medical journal.

[17]  Russell E. Lewis,et al.  Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa , 2005, Antimicrobial Agents and Chemotherapy.

[18]  L. Rice Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria. , 2007, Cleveland Clinic journal of medicine.

[19]  G. Turett,et al.  Polymyxin B Nephrotoxicity and Efficacy against Nosocomial Infections Caused by Multiresistant Gram-Negative Bacteria , 2003, Antimicrobial Agents and Chemotherapy.

[20]  J. Garnacho-Montero,et al.  Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  S. Moestrup,et al.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. , 1995, The Journal of clinical investigation.

[22]  J. Turnidge,et al.  Subacute Toxicity of Colistin Methanesulfonate in Rats: Comparison of Various Intravenous Dosage Regimens , 2008, Antimicrobial Agents and Chemotherapy.

[23]  M. Falagas,et al.  Polymyxins: a review of the current status including recent developments. , 2008, Annals of the Academy of Medicine, Singapore.

[24]  G. Striker,et al.  Colistimethate toxicity. Report of a fatal case in a previously healthy child. , 1969, JAMA.

[25]  S. Hammer,et al.  Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. , 2004, The Journal of antimicrobial chemotherapy.

[26]  K. Ko,et al.  High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. , 2007, The Journal of antimicrobial chemotherapy.

[27]  J. Low,et al.  Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. , 2008, Diagnostic microbiology and infectious disease.

[28]  G. Drusano,et al.  Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.